Abstract
This manuscript reviews published Hsp90 inhibitors and Hsp90-binding compounds. The main goal of the article is to overview the structures of existing Hsp90 inhibitors and to draw correlations between compound structure and binding affinity. Furthermore, it is important to emphasize all thermodynamic binding data especially the data that includes the enthalpies, entropies, heat capacities, and the volumes of binding. This information is important for the goal of drawing the principles of a more rational drug design. The distinction between the observed and the intrinsic binding parameters should also be emphasized. Out of nearly 280 compounds surveyed, most could be classified to three chemical groups (resorcinol-bearing, geldanamycin derivatives, and purine-pyrimidine derivatives) and only few of them have determined intrinsic thermodynamic parameters other than the dissociation/inhibition constant. Since most compounds are being developed as anticancer agents, the available cell growth inhibition data is also included. Possible limitations of the use of enzymatic inhibition and the cancer cell growth inhibition data is discussed.
Keywords: Hsp90, isothermal titration calorimetry, ThermoFluor®, thermal shift assay.
Current Protein & Peptide Science
Title:Inhibitor Binding to Hsp90: A Review of Thermodynamic, Kinetic, Enzymatic, and Cellular Assays
Volume: 15 Issue: 3
Author(s): Vilma Petrikaite and Daumantas Matulis
Affiliation:
Keywords: Hsp90, isothermal titration calorimetry, ThermoFluor®, thermal shift assay.
Abstract: This manuscript reviews published Hsp90 inhibitors and Hsp90-binding compounds. The main goal of the article is to overview the structures of existing Hsp90 inhibitors and to draw correlations between compound structure and binding affinity. Furthermore, it is important to emphasize all thermodynamic binding data especially the data that includes the enthalpies, entropies, heat capacities, and the volumes of binding. This information is important for the goal of drawing the principles of a more rational drug design. The distinction between the observed and the intrinsic binding parameters should also be emphasized. Out of nearly 280 compounds surveyed, most could be classified to three chemical groups (resorcinol-bearing, geldanamycin derivatives, and purine-pyrimidine derivatives) and only few of them have determined intrinsic thermodynamic parameters other than the dissociation/inhibition constant. Since most compounds are being developed as anticancer agents, the available cell growth inhibition data is also included. Possible limitations of the use of enzymatic inhibition and the cancer cell growth inhibition data is discussed.
Export Options
About this article
Cite this article as:
Petrikaite Vilma and Matulis Daumantas, Inhibitor Binding to Hsp90: A Review of Thermodynamic, Kinetic, Enzymatic, and Cellular Assays, Current Protein & Peptide Science 2014; 15 (3) . https://dx.doi.org/10.2174/1389203715666140331115032
DOI https://dx.doi.org/10.2174/1389203715666140331115032 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets Cyclin Dependent Kinase 1 Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry Congenital Malformations Attributed to Prenatal Exposure to Cyclophosphamide
Anti-Cancer Agents in Medicinal Chemistry DNA Methyltransferases Inhibitors from Natural Sources
Current Topics in Medicinal Chemistry Alpha-1-Adrenergic Receptor Blockade Modifies Insulin-Regulated Aminopeptidase (IRAP) Activity in Rat Prostate and Modulates Oxytocin Functions
Drug Metabolism Letters Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer
Current Pharmaceutical Design Chitosan Applications on Pharmaceutical Sciences: A Review
Drug Delivery Letters Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment
Current Medicinal Chemistry Potential Anticancer Properties of Bisphosphonates: Insights From Preclinical Studies
Anti-Cancer Agents in Medicinal Chemistry Astatine Radiopharmaceuticals: Prospects and Problems
Current Radiopharmaceuticals Pharmacological Drug Delivery Strategies for Improved Therapeutic Effects: Recent Advances
Current Pharmaceutical Design Drugs of Abuse: Epigenetic Mechanisms in Toxicity and Addiction
Current Medicinal Chemistry Oral and Intravenous Ibandronate in the Management of Postmenopausal Osteoporosis: A Comprehensive Review
Current Pharmaceutical Design Glycoxidation and Wound Healing in Diabetes: An Interesting Relationship
Current Diabetes Reviews Inhibition of Lysozyme by Taurine Dibromamine
Protein & Peptide Letters Mycotherapy of Cancer: An Update on Cytotoxic and Antitumor Activities of Mushrooms, Bioactive Principles and Molecular Mechanisms of their Action
Current Topics in Medicinal Chemistry The Function of LncRNA FTX in Several Common Cancers
Current Pharmaceutical Design Focal Adhesion Kinase as a Cancer Therapy Target
Anti-Cancer Agents in Medicinal Chemistry Nanoparticulate Drug Delivery System to Overcome the Limitations of Conventional Curcumin in the Treatment of Various Cancers: A Review
Drug Delivery Letters Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology